Human mesenchymal stem cells inhibit vascular permeability by modulating vascular endothelial cadherin/β-catenin signaling

Stem Cells and Development

Volumn 20, Issue 1, 2011, Pages 89-101

  Pati, Shibani ^a   Khakoo, Aarif Y ^b   Zhao, Jing ^a   Jimenez, Fernando ^a   Gerber, Michael H ^a   Harting, Matthew ^a   Redell, John B ^a   Grill, Raymond ^c   Matsuo, Yoichi ^b   Guha, Sushovan ^b   Cox, Charles S ^a   Reitz Jr , Marvin S ^d   Holcomb, John B ^a   Dash, Pramod K ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; BRAIN INJURY; CELL GROWTH; CELL MEMBRANE; CELLULAR DISTRIBUTION; COCULTURE; CONTROLLED STUDY; GENE DISRUPTION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; MALE; MESENCHYMAL STEM CELL; MODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD; BETA CATENIN; BLOOD-BRAIN BARRIER; BRAIN INJURIES; CADHERINS; CAPILLARY PERMEABILITY; CELL MEMBRANE; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED C57BL; PROTEIN BINDING; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; UMBILICAL VEINS;

RODENTIA;

EID: 78650981700     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.2010.0013     Document Type: Article

References (44)

1. Dejana E, F Orsenigo, and MG Lampugnani. (2008). The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci 121:2115-2122.
2. Pittenger MF. (2008). Mesenchymal stem cells from adult bone marrow. Methods Mol Biol 449:27-44.
3. Nemeth K, A Leelahavanichkul, PS Yuen, et al. (2009). Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 15:42-49.
4. Qian H, H Yang, W Xu, et al. (2008). Bone marrow mesenchymal stem cells ameliorate rat acute renal failure by differentiation into renal tubular epithelial-like cells. Int J Mol Med 22:325-332.
5. Le Blanc K, I Rasmusson, B Sundberg, et al. (2004). Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439-1441.
6. Gupta N, X Su, B Popov, et al. (2007). Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 179:1855-1863.
7. Amado LC, AP Saliaris, KH Schuleri, et al. (2005). Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci USA 102:11474-11479.
8. Khakoo AY, S Pati, SA Anderson, et al. (2006). Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposis sarcoma. J Exp Med 203: 1235-1247. (Pubitemid 43736593)
9. Uccelli A, L Moretta and V Pistoia. (2008). Mesenchymal stem cells in health and disease. Nat Rev Immunol 8: 726-736.
10. Pati S, M Cavrois, HG Guo, et al. (2001). Activation of NFkappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposis sarcoma pathogenesis. J Virol 75:8660-8673.
11. Fischer UM, MT Harting, F Jimenez, et al. (2009). Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev 18: 683-692.
12. Lozito TP, JM Taboas, CK Kuo, et al. (2009). Mesenchymal stem cell modification of endothelial matrix regulates their vascular differentiation. J Cell Biochem 107:706-713.
13. Navarro P, L Ruco and E Dejana. (1998). Differential localization of VE-and N-cadherins in human endothelial cells: VE-cadherin competes with N-cadherin for junctional localization. J Cell Biol 140:1475-1484.
14. Crosby CV, PA Fleming, WS Argraves, et al. (2005). VEcadherin is not required for the formation of nascent blood vessels but acts to prevent their disassembly. Blood 105: 2771-2776.
15. Lampugnani MG and E Dejana. (2007). Adherens junctions in endothelial cells regulate vessel maintenance and angiogenesis. Thromb Res 120 (Suppl. 2):S1-S6.
16. Bazzoni G and E Dejana. (2004). Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev 84:869-901.
17. Nelson WJ and R Nusse. (2004). Convergence of Wnt, betacatenin, and cadherin pathways. Science 303:1483-1487.
18. Morin PJ, AB Sparks, V Korinek, et al. (1997). Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275:1787-1790.
19. Roose J and H Clevers. (1999). TCF transcription factors: molecular switches in carcinogenesis. Biochim Biophys Acta 1424:M23-M37.
20. Coghlan MP, AA Culbert, DA Cross, et al. (2000). Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 7:793-803.
21. Potter MD, S Barbero and DA Cheresh. (2005). Tyrosine phosphorylation of VE-cadherin prevents binding of p120-and beta-catenin and maintains the cellular mesenchymal state. J Biol Chem 280:31906-31912.
22. Tetsu O and F McCormick. (1999). Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422-426.
23. Hordijk PL, E Anthony, FP Mul, et al. (1999). Vascular-endothelial- cadherin modulates endothelial monolayer permeability. J Cell Sci 112 (Pt 12):1915-1923.
24. Guo M, JW Breslin, MH Wu, et al. (2008). VE-cadherin and beta-catenin binding dynamics during histamine-induced endothelial hyperpermeability. Am J Physiol Cell Physiol 294:C977-C984.
25. Halama T, G Staffler, S Hoch, et al. (1999). Vascularendothelial cadherin (CD144)-but not PECAM-1 (CD31)-based cell-to-cell contacts convey the maintenance of a quiescent endothelial monolayer. Int Arch Allergy Immunol 120:237-244.
26. Zhao J, AN Moore, GL Clifton, et al. (2005). Sulforaphane enhances aquaporin-4 expression and decreases cerebral edema following traumatic brain injury. J Neurosci Res 82:499-506.
27. Zhao J, AN Moore, JB Redell, et al. (2007). Enhancing expression of Nrf2-driven genes protects the blood brain barrier after brain injury. J Neurosci 27:10240-10248.
28. Taddei A, C Giampietro, A Conti, et al. (2008). Endothelial adherens junctions control tight junctions by VE-cadherinmediated upregulation of claudin-5. Nat Cell Biol 10: 923-934.
29. Corada M, M Mariotti, G Thurston, et al. (1999). Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci USA 96:9815-9820.
30. Carmeliet P, MG Lampugnani, L Moons, et al. (1999). Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98:147-157.
31. Esser S, MG Lampugnani, M Corada, et al. (1998). Vascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells. J Cell Sci 111 (Pt 13):1853-1865.
32. Andriopoulou P, P Navarro, A Zanetti, et al. (1999). Histamine induces tyrosine phosphorylation of endothelial cellto-cell adherens junctions. Arterioscler Thromb Vasc Biol 19:2286-2297.
33. Nawroth R, G Poell, A Ranft, et al. (2002). VE-PTP and VE-cadherin ectodomains interact to facilitate regulation of phosphorylation and cell contacts. EMBO J 21:4885-4895.
34. Dominguez MG, VC Hughes, L Pan, et al. (2007). Vascular endothelial tyrosine phosphatase (VE-PTP)-null mice undergo vasculogenesis but die embryonically because of defects in angiogenesis. Proc Natl Acad Sci USA 104: 3243-3248.
35. Herren B, B Levkau, EW Raines, et al. (1998). Cleavage of beta-catenin and plakoglobin and shedding of VE-cadherin during endothelial apoptosis: evidence for a role for caspases and metalloproteinases. Mol Biol Cell 9:1589-1601.
36. Lampugnani MG, M Resnati, M Raiteri, et al. (1992). A novel endothelial-specific membrane protein is a marker of cell-cell contacts. J Cell Biol 118:1511-1522.
37. Xiao K, DF Allison, MD Kottke, et al. (2003). Mechanisms of VE-cadherin processing and degradation in microvascular endothelial cells. J Biol Chem 278:19199-19208.
38. Karnoub AE, AB Dash, AP Vo, et al. (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449:557-563.
39. Gnecchi M, H He, N Noiseux, et al. (2006). Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 20:661-669.
40. Chen L, EE Tredget, PY Wu, et al. (2008). Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 3:e1886.
41. Chen J, X Cui, A Zacharek, et al. (2009). Increasing Ang1= Tie2 expression by simvastatin treatment induces vascular stabilization and neuroblast migration after stroke. J Cell Mol Med 13:1348-1357.
42. Childs EW, B Tharakan, N Byrge, et al. (2008). Angiopoietin-1 inhibits intrinsic apoptotic signaling and vascular hyperpermeability following hemorrhagic shock. Am J Physiol Heart Circ Physiol 294:H2285-H2295.
43. Zacharek A, J Chen, X Cui, et al. (2007). Angiopoietin1=Tie2 and VEGF=Flk1 induced by MSC treatment amplifies angiogenesis and vascular stabilization after stroke. J Cereb Blood Flow Metab 27:1684-1691.
44. Lee RH, AA Pulin, MJ Seo, et al. (2009). Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5:54-63.